Patterson Companies Company Profile (NASDAQ:PDCO)

Patterson Companies trades on the NASDAQ under the ticker symbol "PDCO."

Patterson Companies declared a quarterly dividend on Tuesday, September 19th. Investors of record on Friday, October 13th will be given a dividend of $0.26 per share on Friday, October 27th. This represents a $1.04 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Thursday, October 12th. View Patterson Companies' Dividend History.

Patterson Companies, Inc. (NASDAQ:PDCO) released its quarterly earnings data on Thursday, August, 24th. The company reported $0.44 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.44. The firm earned $1.30 billion during the quarter, compared to analyst estimates of $1.34 billion. Patterson Companies had a net margin of 2.93% and a return on equity of 15.51%. Patterson Companies's revenue was down 1.4% on a year-over-year basis. During the same period last year, the firm earned $0.51 earnings per share. View Patterson Companies' Earnings History.

Patterson Companies is scheduled to release their next quarterly earnings announcement on Monday, November, 20th 2017. View Earnings Estimates for Patterson Companies.

Patterson Companies issued an update on its FY18 earnings guidance on Thursday, August, 24th. The company provided earnings per share (EPS) guidance of $2.25-2.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.31.

12 analysts have issued twelve-month target prices for Patterson Companies' shares. Their predictions range from $34.00 to $50.00. On average, they anticipate Patterson Companies' stock price to reach $42.22 in the next year. View Analyst Ratings for Patterson Companies.

Here are some recent quotes from research analysts about Patterson Companies stock:

• 1. According to Zacks Investment Research, "The Patterson Companies reported a mixed first quarter of fiscal 2017 wherein adjusted earnings beat the Zacks Consensus Estimate, while revenues missed the same. Patterson Companies’ Dental platform sales dropped significantly on a year-over-year basis in the first quarter, thanks to declining consumables and dental equipment sales. The U.S. dental products distribution industry is highly competitive. Share price movement in the past three months has been disappointing with the stock trading below the broader industry. Furthermore, management expects headwinds in the technology-based equipment business to persist through fiscal 2018 as Patterson Companies has been shifting to the new go-to market strategy with an expanded technology-based product portfolio. Meanwhile, we are upbeat about the company’s Animal Health segment that witnessed strong sales in the last quarter." (9/6/2017)
• 2. UBS AG analysts commented, "tough to fill" even with new product introductions — a view that is shared among others on the Street.The loss of Sirona could also generate further market share losses in consumables sales, which are expected to remain in the low-single digit range, Cherny continued. As such, it is not clear at this point in time if the company will be able to accelerate recent EBIT growth, especially when factoring in expectations for further EBIT margin pressures from the Animal Health mix shift.Meanwhile, Patterson hasn't yet brought in a permanent CEO, and once an executive is appointed, they will need to immediately implement a sales force rebuild, the analyst added. Also, the ongoing ERP investment (Enterprise Resource Planning) and roll-out continues to be an overhang and needs to be managed properly to fully take advantage of any new opportunity.While these issues are indeed fixable and the hiring of a new CEO could "pivot the company in a more sustainable direction," (7/11/2017)
• 3. Stifel Nicolaus analysts commented, "Our accompanying survey diligence (n = 72) highlights near-term market share concerns for Patterson's dental business amid turnover in the company's sales reps and decision not to extend exclusivity for Sirona equipment (largely CEREC and imaging) after September 2017. Longer term, our findings suggest pressure from alternative sources of supply (e.g., Amazon) is creeping into the equation and the prominence of GPOs seems likely to increase, which in short, could shift purchasing power toward the dental practices and curtail future growth. Additionally, competition for large DSO contracts is heating up as evidenced by the recent Patterson / Heartland deal. While Dental and Veterinary continue to offer compelling end market dynamics, the headwinds detailed in our survey keep us on the sidelines with the belief that the lower multiples recently ascribed to these businesses may become the new normal. We reiterate our Hold rating on PDCO and lower our target price to $39 (from $41)." (1/30/2017)

Some companies that are related to Patterson Companies include West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), TESARO (TSRO), Ionis Pharmaceuticals (IONS), Dr. Reddy's Laboratories Ltd (RDY), Bioverativ (BIVV), DexCom (DXCM), Icon Plc (ICLR), bluebird bio (BLUE), Exact Sciences Corporation (EXAS), Envision Healthcare Corporation (EVHC), INC Research Holdings (INCR), Neurocrine Biosciences (NBIX), Galapagos NV (GLPG), Juno Therapeutics (JUNO), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR) and athenahealth (ATHN).

Patterson Companies' management team includes the folowing people:

• James W. Wiltz, Interim President, Interim Chief Executive Officer, Director
• Ann B. Gugino, Chief Financial Officer, Executive Vice President, Treasurer
• David G. Misiak, President - Patterson Dental North America
• Kevin Pohlman, Interim President - Patterson Animal Health
• Kelly A. Baker, Chief Human Resource Officer
• Les B. Korsh, Vice President, General Counsel and Secretary
• John D. Buck, Non-Executive Chairman of the Board
• Alex N. Blanco, Independent Director
• Jody H. Feragen, Independent Director
• Sarena S. Lin, Independent Director

Patterson Companies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.74%), BlackRock Inc. (6.68%), State Street Corp (4.36%), Fairpointe Capital LLC (3.71%), Wells Fargo & Company MN (3.16%) and Kayne Anderson Rudnick Investment Management LLC (1.72%). Company insiders that own Patterson Companies stock include Ann B Gugino, Ellen A Rudnick, James W Wiltz, John D Buck and Scott P Anderson. View Institutional Ownership Trends for Patterson Companies.

Patterson Companies' stock was sold by a variety of institutional investors in the last quarter, including Nuance Investments LLC, Westwood Holdings Group Inc., BlackRock Inc., Farr Miller & Washington LLC DC, Riverbridge Partners LLC, Epoch Investment Partners Inc., Wells Fargo & Company MN and State of Wisconsin Investment Board. Company insiders that have sold Patterson Companies stock in the last year include Ann B Gugino, Ellen A Rudnick, James W Wiltz and Scott P Anderson. View Insider Buying and Selling for Patterson Companies.

Patterson Companies' stock was bought by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Heartland Advisors Inc., Gotham Asset Management LLC, AXA, Shapiro Capital Management LLC, Fisher Asset Management LLC, Schroder Investment Management Group and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Patterson Companies.

Shares of Patterson Companies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Patterson Companies stock can currently be purchased for approximately $37.99.